Article
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting PI3K/AKT Pathway and Activating AMPK/ROS Pathway
2020-12-02
Abstract excerpt
<title>Abstract</title> <p><bold>Background</bold>: Ovarian cancer is the most lethal female genital malignancy. Though cisplatin is still the first-line chemotherapy to treat ovarian cancer patients with debulking surgeries, its efficacy is limited due to the high-incidence of cisplatin resistance. ATP citrate lyase (ACLY) has been proved to be a key metabolic enzyme and was related to poor prognosis in various...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a81be9e2-209d-5ebf-b539-464b0c63d97a
- DOI
- 10.21203/rs.3.rs-117480/v1
